Evidence map›Paper›PMID 21999491›Full record

ArticleACS nano2011

Engineered nanostructures of antigen provide an effective means for regulating mast cell activation.

Zhao Deng, I-Chun Weng, Jie-Ren Li, Huan-Yuan Chen, Fu-Tong Liu, Gang-yu Liu

Abstract read
In one paragraph

Article in ACS nano, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Zhao DengDepartment of Chemistry, University of California, Davis, California 95616, USA.
I-Chun Weng
Jie-Ren Li
Huan-Yuan Chen
Fu-Tong Liu
Gang-yu Liu
University of California, Davis · USInstitute of Biomedical Sciences, Academia Sinica · TW

Funding

Galectin-3 in regulation of allergic skin inflammationR01AR056343 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LIU, FU-TONG · 2010 to 2014
$1.7M
NIAMS NIH HHS AR056343NIAMS NIH HHS R01 AR056343
6 · The paper itself

Abstract

Nanostructures containing 2,4-dinitrophenyl (DNP) as antigen were designed and produced to investigate antibody-mediated activation of mast cells. The design consists of nanogrids of DNP termini inlaid in alkanethiol self-assembled monolayers (SAMs). Using scanning probe-based nanografting, nanometer precision was attained for designed geometry, size, and periodicity. Rat basophilic leukemia (RBL) cells exhibited high sensitivity to the geometry and local environment of DNP presented on these nanostructures. The impact included cellular adherence, spreading, membrane morphology, cytoskeleton structure, and activation. The highest level of spreading and activation was induced by nanogrids of 17 nm line width and 40 nm periodicity, with DNP haptens 1.4 nm above the surroundings. The high efficacy is attributed to two main factors. First, DNP sites in the nanostructure are highly accessible by anti-DNP IgE during recognition. Second, the arrangement or geometry of DNP termini in nanostructures promotes clustering of FcεRI receptors that are prelinked to IgE. The clustering effectively initiates Lyn-mediated signaling cascades, ultimately leading to the degranulation of RBL cells. This work demonstrates an important concept: that nanostructures of ligands provide new and effective cues for directing cellular signaling processes.

Indexed as

Nanotechnology2,4-DinitrophenolAnimalsAntibodiesAntigen PresentationCell AdhesionCell Line, TumorHaptensMast CellsNanostructuresRatsSignal Transduction2,4-DinitrophenolAntibodiesHaptens

Identifiers

PMID21999491
PMCPMC3228856
OpenAlexW2018040196

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.